Wealthcare Advisory Partners LLC Has $274,000 Stock Position in AstraZeneca PLC (NASDAQ:AZN)

Wealthcare Advisory Partners LLC increased its holdings in AstraZeneca PLC (NASDAQ:AZN) by 12.9% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,723 shares of the company’s stock after acquiring an additional 424 shares during the period. Wealthcare Advisory Partners LLC’s holdings in AstraZeneca were worth $274,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Confluence Investment Management LLC acquired a new position in shares of AstraZeneca during the 1st quarter valued at about $27,000. Banque Transatlantique SA bought a new stake in shares of AstraZeneca in the fourth quarter valued at about $26,000. Mascagni Wealth Management Inc. bought a new stake in shares of AstraZeneca during the fourth quarter valued at approximately $29,000. CoreCap Advisors LLC lifted its holdings in shares of AstraZeneca by 31.8% during the 4th quarter. CoreCap Advisors LLC now owns 642 shares of the company’s stock worth $42,000 after acquiring an additional 155 shares during the period. Finally, Financial Management Professionals Inc. boosted its holdings in AstraZeneca by 34.4% during the first quarter. Financial Management Professionals Inc. now owns 781 shares of the company’s stock valued at $57,000 after purchasing an additional 200 shares in the last quarter. 20.35% of the stock is currently owned by hedge funds and other institutional investors.

AstraZeneca Trading Down 0.8%

NASDAQ AZN opened at $74.42 on Friday. The stock has a 50 day moving average of $69.81 and a 200-day moving average of $70.29. AstraZeneca PLC has a 12 month low of $61.24 and a 12 month high of $87.68. The company has a market cap of $230.80 billion, a PE ratio of 32.93, a PEG ratio of 1.42 and a beta of 0.38. The company has a current ratio of 0.93, a quick ratio of 0.74 and a debt-to-equity ratio of 0.65.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings results on Tuesday, April 29th. The company reported $1.24 EPS for the quarter, beating analysts’ consensus estimates of $1.10 by $0.14. The business had revenue of $13.59 billion for the quarter, compared to analyst estimates of $13.71 billion. AstraZeneca had a net margin of 13.01% and a return on equity of 32.23%. AstraZeneca’s quarterly revenue was up 7.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.06 EPS. On average, equities research analysts anticipate that AstraZeneca PLC will post 4.51 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, BNP Paribas began coverage on AstraZeneca in a report on Tuesday, April 15th. They issued an “outperform” rating and a $75.00 price target for the company. One investment analyst has rated the stock with a hold rating, five have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $85.00.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.